AVITA Medical, Inc. (AVHHL) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

AVITA Medical, Inc. (AVHHL) Healthcare & Pipeline Overview

AVITA Medical Inc. is a regenerative medicine company specializing in skin restoration therapies, primarily through its RECELL System for burn treatment. With a focus on expanding applications in trauma and dermatological conditions, AVITA operates in the competitive medical device sector, leveraging its proprietary technology to address unmet needs in skin regeneration.

What Is the Investment Thesis for AVHHL?

AVITA Medical presents a compelling, albeit high-risk, investment thesis centered on its RECELL System and its potential to disrupt the skin regeneration market. The company's gross margin of 82.1% indicates strong pricing power and efficient production. Growth catalysts include expansion into new indications like trauma and chronic wounds, as well as potential regulatory approvals in additional geographies. However, the company's negative P/E ratio of -2.86 and profit margin of -67.8% highlight its current lack of profitability. The company's high beta of 1.81 suggests significant volatility relative to the broader market. Successful commercialization of new applications and strategic partnerships will be critical to achieving sustained growth and profitability.

Based on FMP financials and quantitative analysis

AVHHL Key Highlights

RECELL System is approved for acute thermal burns in patients 18+ in the US, Australia, and the UK.

• Gross margin of 82.1% demonstrates strong pricing power.
• Market capitalization of $192M reflects its current valuation in the regenerative tissue market.
• The company has 260 employees, indicating a substantial operational infrastructure.
• Beta of 1.81 indicates high volatility compared to the market.

Who Are AVHHL's Competitors?

AVHHL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are AVHHL's Key Strengths?

Proprietary RECELL System technology.

• High gross margin of 82.1%.
• Established presence in the burn treatment market.
• Research collaborations with reputable institutions.

What Are AVHHL's Weaknesses?

Negative P/E ratio and profit margin.

• High beta indicating significant volatility.
• Reliance on a single core product (RECELL System).
• Limited geographic presence.

What Could Drive AVHHL Stock Higher?

Potential regulatory approvals for RECELL System in new geographies.

• Expansion of RECELL System into trauma and chronic wound care markets.
• Development of dermatological and aesthetic applications for RECELL System.
• Strategic partnerships and acquisitions to expand product portfolio and market share.
• Clinical trial results demonstrating the efficacy of RECELL System in new indications.

What Are the Key Risks for AVHHL?

Financial-distress signal — its Altman Z-Score of -13.59 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Competition from established wound care companies.
• Regulatory hurdles and approval delays.
• Risk of product liability claims.
• Technological obsolescence.
• Negative P/E ratio and profit margin indicating financial instability.

What Are the Growth Opportunities for AVHHL?

• Expansion into Trauma Indications: AVITA Medical has a significant growth opportunity in expanding the use of the RECELL System for trauma injuries. The market for trauma care is substantial, driven by accidents, surgeries, and other traumatic events. By demonstrating the efficacy of RECELL in treating trauma-related skin injuries, AVITA can tap into a large and underserved market. This expansion requires further clinical trials and regulatory approvals, but the potential revenue impact is considerable. Timeline: 2-3 years for clinical trials and regulatory approvals.
• Chronic Wound Care Market: The chronic wound care market, including diabetic ulcers and pressure sores, represents another significant growth opportunity for AVITA Medical. Chronic wounds are a major healthcare burden, and the RECELL System's regenerative properties could offer a more effective treatment option compared to traditional methods. Penetrating this market requires clinical data demonstrating the superiority of RECELL in chronic wound healing. Timeline: 3-5 years for clinical trials and market penetration.
• Dermatological and Aesthetic Applications: AVITA Medical is exploring the use of the RECELL System for dermatological and aesthetic applications, such as vitiligo treatment. The market for aesthetic procedures is large and growing, driven by increasing consumer demand for skin rejuvenation and correction. Successful development and commercialization of RECELL for these applications could significantly expand AVITA's revenue streams. Timeline: 2-4 years for product development and market launch.
• Geographic Expansion: AVITA Medical has the opportunity to expand its geographic reach beyond the United States, Australia, and the United Kingdom. Entering new markets, such as Europe and Asia, requires regulatory approvals and the establishment of distribution networks. However, the potential revenue gains from expanding into these large markets are substantial. Timeline: 2-5 years for regulatory approvals and market entry.
• Strategic Partnerships and Acquisitions: AVITA Medical can pursue growth through strategic partnerships and acquisitions. Collaborating with other companies in the regenerative medicine space can provide access to new technologies, markets, and expertise. Acquiring complementary businesses can expand AVITA's product portfolio and market share. Timeline: Ongoing, as opportunities arise.

What Are AVHHL's Competitive Advantages?

• Patented RECELL System technology provides a competitive advantage.
• Proprietary platform technology based on regenerative properties of skin cells.
• Established presence in the burn treatment market.
• Research collaborations with leading medical institutions.

What Does AVHHL Do?

AVITA Medical Inc., founded in 2000 and based in Valencia, California, is a commercial-stage regenerative tissue company dedicated to addressing unmet medical needs through innovative solutions derived from a patient's own skin. The company's core technology is centered around its patented and proprietary platform that harnesses the regenerative properties of skin cells to treat a variety of conditions, including burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetic indications such as vitiligo. AVITA's lead product, the RECELL System, is a medical device that enables healthcare professionals to create a suspension of Spray-On Skin cells using a small sample of the patient's own skin. This suspension is then applied to the affected area, promoting natural healing and reducing the need for extensive skin grafting. The RECELL System is currently approved for use in the treatment of acute thermal burns in patients eighteen years and older in the United States, Australia, and the United Kingdom. AVITA Medical is also engaged in research collaborations to explore new applications for its technology, including a partnership with the University of Colorado School of Medicine to develop a spray-on treatment for genetically corrected cells and a collaboration with Houston Methodist Research Institute to investigate molecular reversal of cellular aging through a novel cell suspension delivery system. Formerly known as AVITA Therapeutics, Inc., the company changed its name to AVITA Medical Inc. in December 2020 to better reflect its focus on regenerative medicine.

What Products and Services Does AVHHL Offer?

• Develops and commercializes regenerative tissue products.
• Offers RECELL System for burn treatment.
• Provides Spray-On Skin cells derived from a patient's own skin.
• Addresses unmet medical needs in burn injuries.
• Targets trauma injuries and chronic wounds.
• Explores dermatological and aesthetic applications.
• Conducts research collaborations for new applications.

How Does AVHHL Make Money?

• Sells the RECELL System device to hospitals and clinics.
• Generates revenue from the sale of consumables used with the RECELL System.
• Pursues research collaborations and licensing agreements.
• Seeks regulatory approvals for new indications and geographies.

What Industry Does AVHHL Operate In?

AVITA Medical operates within the medical device industry, specifically in the regenerative medicine segment. This sector is characterized by rapid innovation, increasing demand for advanced wound care solutions, and stringent regulatory oversight. The market for wound care and skin regeneration is projected to grow, driven by factors such as an aging population, rising incidence of chronic diseases like diabetes, and increasing awareness of advanced treatment options. AVITA competes with companies offering traditional skin grafting techniques and other advanced wound care products. Key trends include the development of cell-based therapies, bioengineered skin substitutes, and minimally invasive treatment options.

Who Are AVHHL's Key Customers?

• Hospitals and burn centers.
• Dermatologists and aesthetic clinics.
• Trauma centers and wound care specialists.
• Patients with burn injuries.
• Patients with trauma injuries and chronic wounds.

Wall Street analysts project AVITA Medical, Inc. revenue of about $83.1M for fiscal 2026, with EPS near $-0.21. The estimate reflects 6 contributing analysts.

Quarterly Financial Performance: AVITA Medical, Inc.

Revenue for AVITA Medical, Inc. came in at $21.7M during Q2 2026, a 12.7% improvement versus the preceding quarter. The company recorded a net loss of $7.7M, with diluted EPS of $-0.25. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, AVHHL averaged $-0.36 in diluted EPS.

AVHHL Valuation & Market Position

With a $192M market cap, AVITA Medical, Inc. sits in the micro-cap segment of the market. Relative to its peer group, AVHHL's quantitative score of 48/100 is roughly in line with the peer average of 50/100.

Return on equity for AVITA Medical, Inc. stands at 305.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -88.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -30.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.47 means current liabilities exceed short-term assets, a liquidity point worth watching.

AVITA Medical, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -13.59 places it in the distress zone, a signal of elevated financial risk.

Company Profile

AVITA Medical, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Valencia, US. The company is led by CEO Cary G. Vance. AVHHL has traded publicly since 2003.

AVHHL Financials

AVHHL Latest News

No recent news available for AVHHL.

AVHHL Analyst Consensus

AVHHL MoonshotScore

What Investors Ask About AVITA Medical, Inc. (AVHHL) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources